Niagen Bioscience, Inc. (NAGE)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Niagen Bioscience, Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 3 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 3.40 $ — 3% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 270.6% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- 0.03 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.09 | 5,690.60 | 29 | 37.40 | 24.60 | 9 | 9 |
| 2025: Q1 | 0.06 | – | 31 | 37.60 | 16.60 | 8 | 8 |
| 2025: Q2 | 0.04 | – | 31 | 36.80 | 11.60 | 1 | 1 |
| 2025: Q3 | 0.05 | 118.90 | 34 | 32.90 | 13.50 | 4 | 4 |
| 2025: Q4 | 0.05 | -44.30 | 34 | 16.20 | 12.20 | 1 | 1 |
| 2026: Q1 | 0.07 | 22.80 | 32 | 3.30 | 20.10 | -1 | -1 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products.
| Employees | 117 |
|---|---|
| Headquarters | Los Angeles, CA |
| Website | niagenbioscience.com |
| IPO Date | 15. Jul 2008 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Frank Louis Jaksch Jr. | Co-Founder & Chairman | 1968 |
| Robert N. Fried | CEO & Director | 1960 |
| Ozan Pamir C.F.A. | CFO & Principal Accounting Officer | 1992 |
| Carlos Lopez | Senior VP & General Counsel | 1981 |
| Andrew Shao Ph.D. | Senior Vice President of Global Regulatory & Scientific Affairs | – |
| Michiko Kelley | Chief Marketing Officer | – |
| Chu Yan | Managing Director of Asia Pacific | – |
| Kendall Knysch | Head of Media Relations & Partnerships | – |
| James Lee | Controller | 1976 |
| Wesley Yu | Vice President of Finance | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 30. Jun 2026 | Lopez Carlos Luis | SVP, General Counsel | Other | 2,314 | 2.71 | 6,271 |
| 30. Jun 2026 | Pamir Ozan | Chief Financial Officer | Other | 4,255 | 2.71 | 11,531 |
| 30. Jun 2026 | Fried Robert N | Chief Executive Officer | Other | 1,106 | 2.71 | 2,997 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.